Holen Sie sich die Stockscreener-App
192.73
1.33%
-1.49
Schlusskurs vom Vortag:
$194.22
Offen:
$194.57
24-Stunden-Volumen:
294.19K
Relative Volume:
0.12
Marktkapitalisierung:
$40.79B
Einnahmen:
$398.11M
Nettoeinkommen (Verlust:
$-1.03B
KGV:
-33.79
EPS:
-5.7032
Netto-Cashflow:
$-868.57M
1W Leistung:
+20.03%
1M Leistung:
+33.07%
6M Leistung:
+166.16%
1J Leistung:
+184.83%
1-Tages-Spanne:
$191.33
$197.08
1-Wochen-Bereich:
$160.53
$197.08
52-Wochen-Spanne:
$60.40
$197.08
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Vergleichen Sie INSM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
192.96 | 41.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.11 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
652.39 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.36 | 58.93B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
817.00 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
RBC Raises Price Target on Insmed to $215 From $139, Keeps Outperform Rating - MarketScreener
Insmed Misses on Q3 Earnings, Stock Rises on Strong Brinsupri Uptake - Zacks Investment Research
Insmed Reaches Analyst Target Price - Nasdaq
What machine learning models say about Insmed IncorporatedJuly 2025 PreEarnings & AI Enhanced Trade Execution Alerts - newser.com
Biotech Stocks Hit 52-Week Highs: MTSR, INSM, ABVX, MAZE Lead October 30 Surge - RTTNews
Why Insmed Incorporated is moving today2025 Fundamental Recap & Free Community Consensus Stock Picks - newser.com
Insmed Q3 2025 Earnings Call Transcript - MarketBeat
Insmed earnings missed by $0.41, revenue topped estimates - Investing.com Canada
Will Insmed Incorporated (IM8N) stock see valuation expansionEarnings Growth Report & Free Fast Gain Swing Trade Alerts - newser.com
A Look at Insmed (INSM) Valuation Following EU Brensocatib Milestone and ARIKAYCE Revenue Upgrade - Yahoo Finance
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed stock price target raised to $223 by TD Cowen on strong Brinsupri launch - Investing.com Nigeria
Insmed Incorporated (INSM) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
INSM: On the Rise Again or Just a Bubble? - StocksToTrade
Insmed Inc (INSM) Q3 2025 Earnings Call Highlights: Strong Launch for Brin Suri and Robust ... - Yahoo! Finance UK
Insmed stock hits 52-week high at 170.3 USD By Investing.com - Investing.com South Africa
Insmed Incorporated Raises Global ARIKAYCE Revenue Guidance for the Full Year 2025 - MarketScreener
Insmed Reports Strong Sales Growth And Raises Guidance For 2025 - Finimize
Insmed Q3 2025 slides reveal strong BRINSUPRI debut, ARIKAYCE growth accelerates - Investing.com
Insmed’s Promising Future: Are Gains Imminent? - StocksToTrade
Is Insmed Incorporated (IM8N) stock among top earnings playsTrade Risk Assessment & Growth Oriented Trading Recommendations - newser.com
How Insmed Incorporated stock reacts to Fed rate cutsEarnings Recap Report & Technical Confirmation Trade Alerts - newser.com
Insmed’s Strong Financial Performance and Promising Product Launches Reinforce Buy Rating - TipRanks
Earnings call transcript: Insmed Q3 2025 sees revenue beat, stock surges - Investing.com
Insmed: Q3 Earnings Snapshot - CTPost
Insmed (INSM) 2025 Revenue Projections Reach $473.05 Million - GuruFocus
Insmed (INSM) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance
INSM Surpasses Q3 Revenue Expectations Amid New Product Launch - GuruFocus
Insmed Q3 Loss Widens, Revenue Rises; Shares up - MarketScreener
Insmed Inc (INSM) Q3 2025 Earnings: EPS of -$1.25 Beats Estimates, Revenue Surges to $142.4 Million - GuruFocus
Earnings Flash (INSM) Insmed Posts Q3 Loss $1.75 a Share, vs. FactSet Est of $1.33 Loss - MarketScreener
Historical volatility pattern of Insmed Incorporated visualizedWeekly Market Outlook & Safe Entry Trade Signal Reports - newser.com
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Can Insmed Incorporated stock deliver surprise earnings beatJuly 2025 Volume & Fast Gaining Stock Reports - newser.com
Insmed Incorporated stock volume spike explainedRecession Risk & Long-Term Safe Investment Plans - newser.com
Gear Up for Insmed (INSM) Q3 Earnings: Wall Street Estimates for Key Metrics - sharewise.com
What indicators show strength in Insmed IncorporatedBuy Signal & High Accuracy Buy Signal Tips - newser.com
Is a relief rally coming for Insmed Incorporated holdersTrade Analysis Summary & Safe Swing Trade Setups - newser.com
Will Insmed Incorporated stock outperform Dow Jones indexEarnings Risk Summary & Reliable Price Breakout Signals - newser.com
Can Insmed Incorporated stock hit analyst price targetsJuly 2025 Decliners & Intraday High Probability Setup Alerts - Fundação Cultural do Pará
Will Insmed Incorporated stock outperform value stocks2025 Support & Resistance & Verified Technical Trade Signals - Fundação Cultural do Pará
What dividend safety score for Insmed Incorporated stockSwing Trade & Technical Pattern Based Buy Signals - newser.com
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Insmed Inc-Aktie (INSM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schaeffer Orlov S Nicole | Chief People Strategy Officer |
Sep 12 '25 |
Sale |
145.45 |
76,520 |
11,129,927 |
36,461 |
| SHAROKY MELVIN MD | Director |
Sep 12 '25 |
Sale |
145.39 |
10,000 |
1,453,900 |
262,675 |
0.62%
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):